Q-omics provides the consensus-scored TSPAN33 profile across patient tissues and cancer cell-line models. TSPAN33 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TSPAN33 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TSPAN33 RNA expression shows 12,730 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where TSPAN33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN33 survival associations across molecular data types. TSPAN33 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN33 RNA expression–survival associations across cancer types. High TSPAN33 expression shows unfavorable associations in UVM and LIHC, but favorable associations in SKCM, PAAD, CESC and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TSPAN33 RNA expression.
This table summarizes TSPAN33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN33 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in UCEC, LUAD and LIHC. The KIRC box plot shows higher TSPAN33 RNA expression in normal versus tumor tissue (log2 FC = −1.678, t-test p < 0.001).
This table shows molecular features associated with TSPAN33 in patient tissues and cancer cell lines. In patient samples, TSPAN33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
